Official title and information are available only for Plus and Premium subscribers.
Patent Pending Thrombolysis mainly involves the use of thrombolytic drugs, which dissolve blood clots. These drugs are either derived from Streptococcus species, or, more recently, using recombinant biotechnology whereby tPA is manufactured by bacteria, resulting in a recombinant tissue plasminogen activator or rtPA.
To see the additional information details please login and subscribe to a Plus or Premium account.
